Latest / Stock Movers / American Tower Gains, Honeywell Lifts Earnings Outlook, Pfizer Shares Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios podcasts, radio news.
- 0:08Speaker 2: The Stock Movers podcast, your roundup of companies making moves
- 0:13Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:17Speaker 1: Let's get a check on some stocks that are on
- 0:19Speaker 1: the move today with us as Bloomberg News Cross Asset
- 0:22Speaker 1: reporter Isabelle Lee. Isabelle, what are you watch him?
- 0:25Speaker 3: American Towers, so shares are edging higher by almost five percent,
- 0:29Speaker 3: and that's after the company reported earnings that beat expectations
- 0:32Speaker 3: and give an outlook that is seen as positive. So
- 0:34Speaker 3: American Tower is a wireless communications real estate investment trust,
- 0:40Speaker 3: So that took me a while to really understand. So
- 0:42Speaker 3: for the first quarter that adjusted EBITA was hired in estimates,
- 0:45Speaker 3: as was the revenue, and for the year ahead it
- 0:47Speaker 3: was the same story. We have Key Bank Capital Markets
- 0:49Speaker 3: seeing the results are positive and the better than expected
- 0:52Speaker 3: on key Metrics results was great. We have Cities saying
- 0:55Speaker 3: the same thing, the results are positive, and we have
- 0:57Speaker 3: more at Nathanson saying that these are strong results and
- 1:00Speaker 3: they said that this boats well for the growth over
- 1:02Speaker 3: the coming periods. You're also looking at shares of Honeywell
- 1:06Speaker 3: Right gaining almost five percent today, yes, lots of green
- 1:09Speaker 3: on the screen, so honeywell, that's an industrial conglomerate. They
- 1:11Speaker 3: raise their folio guidance for their EPs. So the company,
- 1:14Speaker 3: which plants to split the company into three separate companies,
- 1:18Speaker 3: also said that they will use a multi prong approach
- 1:20Speaker 3: to offset around five hundred million dollars in TIREFF exposure.
- 1:24Speaker 3: So this includes targeting, pricing moves and finding alternative sources
- 1:27Speaker 3: for supplies. And still the outlook for the demand remains uncertain.
- 1:30Speaker 3: We have JP Morgan giving a nuanced comment. They said
- 1:33Speaker 3: that quote, it's a solid quarter, though not quite as
- 1:35Speaker 3: strong as the headline suggests, with most of the upside
- 1:38Speaker 3: from the below the line items for the first quarter.
- 1:40Speaker 3: They also gave a nod. They said that raising the eps'
- 1:42Speaker 3: outlook and offsetting the five hundred million dollars of tire
- 1:44Speaker 3: for exposure reflects agile operational execution.
- 1:49Speaker 1: All right, you're also watching shares of Pfizer in the
- 1:51Speaker 1: pharmer space. What's going on with Pfizer?
- 1:53Speaker 3: This is also edging higher by nearly four percent, So
- 1:55Speaker 3: the company is cutting another one point two billion dollars
- 1:58Speaker 3: from its spending while they really search for the next
- 2:00Speaker 3: big hit. We know that their ob City pill failed.
- 2:03Speaker 3: In an interview with Bloomberg, the CEO said it expects
- 2:06Speaker 3: to pull off three or two or three deals totally
- 2:09Speaker 3: as much as fifteen billion dollars this year, really just
- 2:11Speaker 3: to replenish the pipeline after again the failed ob City pill.
- 2:15Speaker 3: So the company's first quader revenue also fell short estimates,
- 2:18Speaker 3: but they did maintain their twenty twenty five outlooks. So
- 2:20Speaker 3: we talked about this early, and it's interesting that investors
- 2:23Speaker 3: are choosing to focus on the positive, because sometimes they
- 2:25Speaker 3: choose to focus on the negative. The company didn't give
- 2:28Speaker 3: details though on how existing TIFFs will impact their business,
- 2:30Speaker 3: so that's another ambiguity right there.
- 2:33Speaker 1: YEA, for four straight days, Well, it's pretty remarkable. I mean,
- 2:35Speaker 1: I'm zooming out on the chart right now. I'm looking
- 2:37Speaker 1: at its high back on December of twenty twenty one.
- 2:40Speaker 1: This is remember at the height of the COVID pandemic,
- 2:43Speaker 1: when it was one of the two well, I don't
- 2:44Speaker 1: want to say one of the two, but one of
- 2:45Speaker 1: several shots that were approved, one of the two mRNA
- 2:48Speaker 1: vaccines that were approved here in the US. Down fifty
- 2:51Speaker 1: four percent, absolutely, so.
- 2:53Speaker 3: They've really struggled amid the declining demand for COVID vaccines, Like,
- 2:56Speaker 3: I mean, who was even maybe some people are actually
- 2:59Speaker 3: still to making those shots. But what's the next big
- 3:02Speaker 3: thing for them? I mean, it can't be a one
- 3:04Speaker 3: hit wonder, and they have a sivers of multi billion
- 3:06Speaker 3: dollar acquisitions and that still really hasn't panned out.
- 3:09Speaker 1: Yeah, and the weight loss hiccup too that they had,
- 3:11Speaker 1: especially competing with a company such as Novo Nordisk and
- 3:14Speaker 1: Eli Lilly.
- 3:15Speaker 3: Yes, so we'll see what happens to them, but for
- 3:17Speaker 3: now it's looking like they might have something after that
- 3:22Speaker 3: failed a visit to pill But for you're right, five
- 3:25Speaker 3: years with that time horizon, they're down thirty percent.
- 3:29Speaker 2: The Stock Movers podcast from Bloomberg Radio. Check back with
- 3:34Speaker 2: us throughout the day for the latest roundup of companies
- 3:36Speaker 2: making news on Wall Street and for the latest market
- 3:39Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:44Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:47Speaker 2: the Bloomberg Business app.